← ANALYST RATINGS · TIPRANKS
Unicycive Therapeutics (UNCY): analyst forecast and price target
Analyst consensus
Strong Buy3 Buy0 Hold0 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $19.33, the highest $25.00, the lowest $13.00. The average is +475.4% from the last price of $3.36.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $4.00 → $3.50−12.5% | Hold | +4.2% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $4.00 → $3.50−12.5% | Sell | +4.2% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $4.00 → $3.50−12.5% | Hold | +4.2% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $4.00 → $3.50−12.5% | Sell | +4.2% | Downgrade | 14.10.26on TipRanks 10:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $4.00 → $3.50−12.5% | Hold | +4.2% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $4.00 → $3.50−12.5% | Hold | +4.2% | Reiterated | 14.10.26on TipRanks 10:06 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $13.00 | Buy | +286.9% | Reiterated | 30.09.26on TipRanks Sep 29 11:35 | −1.8%next day +3.4% · 5 days −9.0% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $13.00 → $15.00+15.4% | Buy | +346.4% | Reiterated | 20.08.26on TipRanks 07:30 | −1.5%next day +2.9% · 5 days −0.2% | ↗ |
| Jason McCarthy★★★★★★★★★★#12398 · hits 30% · avg −13.6% | Maxim Group | $30.00 | Buy | +792.9% | Reiterated | 17.08.26on TipRanks Aug 18 13:05 | +1.6%next day +1.8% · 5 days −2.9% | ↗ |
| Mayank Mamtani★★★★★★★★★★#2653 · hits 38% · avg +5.8% | B. Riley Securities | $22.00 → $20.00−9.1% | Buy | +495.2% | Reiterated | 13.08.26on TipRanks 09:35 | −0.5%next day +2.2% · 5 days +2.9% | ↗ |
| Robert LeBoyer★★★★★★★★★★#12335 · hits 27% · avg −14.2% | Noble Financial | $50.00 | Buy | +1,388.1% | Reiterated | 13.08.26on TipRanks 09:10 | −0.5%next day +2.2% · 5 days +2.9% | ↗ |
| Vamil Divan★★★★★★★★★★#458 · hits 59% · avg +13.5% | Guggenheim | $37.00 → $25.00−32.4% | Buy | +644.0% | Reiterated | 12.08.26on TipRanks Aug 13 07:10 | +7.5%next day −0.5% · 5 days +4.0% | ↗ |
| Yasmeen Rahimi★★★★★★★★★★#160 · hits 51% · avg +36.0% | Piper Sandler | $90.00 | Buy | +2,578.6% | Reiterated | 01.06.26on TipRanks Jun 2 01:40 | +2.7%next day −5.0% · 5 days −9.8% | ↗ |
| Unknown Analyst | Westpark Capital | $72.00 | Buy | +2,042.9% | Initiated | 19.02.26on TipRanks Feb 20 08:55 | +2.5%next day −4.3% · 5 days +4.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Unicycive Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $25.50 at a price of $4.70 (+443.1%); now: $25.50 at $3.36 (+658.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 8 | 8 | 7 | 6 | 5 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.35 (from $-0.66 to $-0.23). Last quarter: $-0.06.
Best top-analyst consensus in the sector · Healthcare
About Unicycive Therapeutics
- CEO: Shalabh K. Gupta
- Employees: 21
- 1975 West El Camino Real, Mountain View, CA, 94040, US
- www.unicycive.com
Unicycive Therapeutics, Inc. is a U.S.-based biotechnology company dedicated to the creation of innovative treatments for kidney diseases. Its development pipeline includes Renazorb, a therapy for hyperphosphatemia in chronic kidney disease patients, and UNI 494, which is being developed to treat acute kidney injury. Founded in 2016, the firm is headquartered in Los Altos, California.
Data from the stock’s TipRanks forecast page, read 126 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗